The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI

Yim, Hyeona; Yang, Su Geun; Jeon, Yong Sun; Park, In Suh; Kim, Mina; Lee, Don Haeng; Bae, You Han; Na, Kun

doi:10.1016/j.biomaterials.2011.03.069

Cited by 64 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the result of the local LINFU application, a very good T 1 contrast enhancement 44 (180 ± 26%) was detected in the lesion, thus paving the way for future preclinical/clinical translations.…”

Section: < Tmentioning

confidence: 91%

Release of a Paramagnetic Magnetic Resonance Imaging Agent from Liposomes Triggered by Low Intensity Non-Focused Ultrasound

Giustetto¹,

Castelli²,

Boffa³

et al. 2013

J Med Imaging Hlth Inform

View full text Add to dashboard Cite

Pulsed Low Intensity Non-Focused Ultrasound (LINFU) was used to trigger the release from liposomes of the clinically approved Magnetic Resonance Imaging (MRI) agent Gadoteridol. The extent of the release was monitored by relaxometric measurements upon changing both ultrasound stimulus (power, application times and mode, duty cycle values) and physico-chemical variables of the theranostic agent (liposomes size, shape, chemical composition, and concentration of the encapsulated agent). The release was not heat-mediated, but promoted by mechanical interactions between the acoustic radiation waves and the soft nanovesicles. The application of pulsed LINFU led to a controlled release detectable by both Nuclear Magnetic Resonance (NMR) relaxometry and MRI. Such promising observations were followed by an in vivo proof-of-concept study on a syngeneic B16 melanoma mouse model. The obtained results demonstrated the great potential of LINFU for designing MRI-guided protocols aimed at visualizing the release of drugs from liposomal carriers. This study could bring to the development of a new therapeutic for personalized medicine.

show abstract

Section: < Tmentioning

confidence: 91%

Release of a Paramagnetic Magnetic Resonance Imaging Agent from Liposomes Triggered by Low Intensity Non-Focused Ultrasound

Giustetto¹,

Castelli²,

Boffa³

et al. 2013

J Med Imaging Hlth Inform

View full text Add to dashboard Cite

show abstract

“…4. Synthesis of (a) maleilated pullulan and (b) diethylene triamine pentaacetate dianhydride pullulan (Yim et al, 2011). cells, due to their presence on polarized epithelia's apical membrane. While using these folate receptors, the therapeutic index of the drug can be increased.…”

Section: Miscellaneous Pullulan Derivativesmentioning

confidence: 99%

“…DTPA pullulan can also be used for magnetic resonance imaging of the heptocytes for cancer treatment. Yim et al (2011) used gadolinium as contrast agent and coupled with DTPA pullulan. They reported that gadolinium-DTPA pullulan conjugate accumulates in liver and shows higher contrast of the heptocytes with delayed MRI.…”

Section: Miscellaneous Pullulan Derivativesmentioning

confidence: 99%

Pullulan and pullulan derivatives as promising biomolecules for drug and gene targeting

Singh

Kaur

Kennedy³

2015

Carbohydrate Polymers

228

View full text Add to dashboard Cite

“…16 Yim et al reported a pullulan-conjugated gadolinium diethylenetriamine pentaacetate (Gd-DTPA-Pullulan) as hepatocyte-specific contrast agent. 28 Through the specific accumulation of pullulan on hepatocytes via asialoglycoprotein receptors, the Gd-DTPA-pullulan showed three times greater contrast enhancement than un-decorated Gd-DTPA in MRI on orthotopic rat hepatocarcinoma. Hepatic targeting gene delivery vector made from pullulan was also reported.…”

Section: Introductionmentioning

confidence: 96%

High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting

Bian

Huang

et al. 2013

J. Biomed. Mater. Res.

View full text Add to dashboard Cite

pH-sensitive pullulan-doxorubicin (DOX) conjugates were synthesized by attaching DOX onto pullulan derivate through hydrazone bond that was stable under neutral environment but readily cleaved under mildly acidic condition. By changing the feed ratio of DOX to the pullulan derivate, conjugates with drug-loading content up to 30 wt % were obtained. In aqueous solution, the conjugates spontaneously formed uniform core-shell structured nanoparticles with DOX as core and pullulan as shell. The diameters of the nanoparticles ranged from 50 to 110 nm according to the drug-loading content. In vitro releasing experiments showed that more than 75% DOX released within 2 h at pH 5.0, while less than 15% DOX released after 12 h at pH 7.4. This pH-responsive manner of DOX release might assist the quick diffusion of DOX from the acidic endosome/lysosome and the intracellular transfer into the nucleus. Pullulan on the nanoparticles surface provided the nanoparticles with active targeting property to hepatic cells through specific interaction with asialoglycoprotein receptors on the membrane of hepatic cells, without the necessity of introducing any extra ligand. These pullulan-DOX conjugate nanoparticles were expected to be promising drug delivery system for liver targeting antitumor chemotherapy.

show abstract

The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI

Cited by 64 publications

References 33 publications

Release of a Paramagnetic Magnetic Resonance Imaging Agent from Liposomes Triggered by Low Intensity Non-Focused Ultrasound

Release of a Paramagnetic Magnetic Resonance Imaging Agent from Liposomes Triggered by Low Intensity Non-Focused Ultrasound

Pullulan and pullulan derivatives as promising biomolecules for drug and gene targeting

High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting

Contact Info

Product

Resources

About